BMY

Bristol Myers Squibb (BMY)

Bristol Myers Squibb Co

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NYSE:BMY

1 2 3 4 5 6 7 8 9 10 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2025/01/03	20 : 59	Business Wire	Bristol Myers Squibb to Present at J.P. Morgan’s 43rd Annual Healthcare Conference	NYSE:BMY	Bristol Myers Squibb Co
2024/12/28	07 : 37	Business Wire	U.S. Food and Drug Administration Approves Opdivo Qvantig™ (nivolumab and hyaluronidase-nvhy) Injection, for Subcutaneous Use in Most Previously Approved Adult, Solid Tumor Opdivo® (nivolumab) Indications1,2	NYSE:BMY	Bristol Myers Squibb Co
2024/12/23	20 : 59	Business Wire	Bristol Myers Squibb Announces Positive Topline Results from Two Pivotal Phase 3 Trials Evaluating Sotyktu (deucravacitinib) in Adults with Psoriatic Arthritis	NYSE:BMY	Bristol Myers Squibb Co
2024/12/23	20 : 45	Business Wire	Bristol Myers Squibb Receives European Commission Approval for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite Instability–High or Mismatch Repair Deficient Metastatic Colorectal Cancer	NYSE:BMY	Bristol Myers Squibb Co
2024/12/19	20 : 59	Business Wire	Bristol Myers Squibb to Report Results for Fourth Quarter 2024 on February 6, 2025	NYSE:BMY	Bristol Myers Squibb Co
2024/12/12	06 : 17	Business Wire	Bristol Myers Squibb Announces Dividend Increase	NYSE:BMY	Bristol Myers Squibb Co
2024/12/10	07 : 45	Business Wire	Bristol Myers Squibb Highlights Progress of Cell Therapy Portfolio at ASH 2024 with Long-Term Survival Data and Results from Expanding Pipeline	NYSE:BMY	Bristol Myers Squibb Co
2024/11/26	20 : 59	Business Wire	Bristol Myers Squibb to Participate in Citi’s 2024 Global Healthcare Conference	NYSE:BMY	Bristol Myers Squibb Co
2024/11/19	20 : 59	Business Wire	Bristol Myers Squibb’s Presentations at ASH 2024 Reinforce Strength of Hematology Portfolio and Scientific Advances in Differentiated Research Platforms	NYSE:BMY	Bristol Myers Squibb Co
2024/11/15	22 : 23	Business Wire	Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite Instability–High or Mismatch Repair Deficient Metastatic Colorectal Cancer	NYSE:BMY	Bristol Myers Squibb Co
2024/11/15	20 : 59	Business Wire	Bristol Myers Squibb Receives Positive CHMP Opinion for Repotrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer and Advanced NTRK-Positive Solid Tumors	NYSE:BMY	Bristol Myers Squibb Co
2024/11/13	06 : 05	GlobeNewswire Inc.	Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal 3Q 2024 Results	NYSE:BMY	Bristol Myers Squibb Co
2024/11/11	20 : 59	Business Wire	Bristol Myers Squibb Showcases the Continued Strength of its Cardiovascular Portfolio with New Clinical and Real-World Data at American Heart Association Scientific Sessions 2024	NYSE:BMY	Bristol Myers Squibb Co
2024/11/06	07 : 53	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NYSE:BMY	Bristol Myers Squibb Co
2024/11/06	07 : 50	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NYSE:BMY	Bristol Myers Squibb Co
2024/11/06	07 : 48	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NYSE:BMY	Bristol Myers Squibb Co
2024/11/06	07 : 42	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NYSE:BMY	Bristol Myers Squibb Co
2024/11/06	07 : 41	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NYSE:BMY	Bristol Myers Squibb Co
2024/11/06	07 : 00	Business Wire	Bristol Myers Squibb to Participate in Upcoming Investor Conferences	NYSE:BMY	Bristol Myers Squibb Co
2024/11/01	05 : 16	Business Wire	Bristol Myers Squibb Presents New Long-term Data from the EMERGENT Program Evaluating COBENFY™ (xanomeline and trospium chloride) in Adults with Schizophrenia at Psych Congress 2024	NYSE:BMY	Bristol Myers Squibb Co
2024/10/31	19 : 59	Business Wire	Bristol Myers Squibb Reports Third Quarter Financial Results for 2024	NYSE:BMY	Bristol Myers Squibb Co
2024/10/28	19 : 59	Business Wire	Bristol Myers Squibb to Present New Clinical and Health Economics and Outcomes Research Data at Psych Congress 2024	NYSE:BMY	Bristol Myers Squibb Co
2024/10/04	06 : 35	Business Wire	U.S. Food and Drug Administration Approves Perioperative Treatment of Neoadjuvant Opdivo® (nivolumab) and Chemotherapy Followed by Surgery and Adjuvant Single-Agent Opdivo for Resectable Non-Small Cell Lung Cancer (NSCLC)	NYSE:BMY	Bristol Myers Squibb Co
2024/09/30	20 : 00	GlobeNewswire Inc.	Prime Medicine Announces Strategic Research Collaboration and License Agreement with Bristol Myers Squibb to Develop and Commercialize Multiple Prime Edited Ex Vivo T-Cell Therapies	NYSE:BMY	Bristol Myers Squibb Co
2024/09/28	08 : 38	Business Wire	U.S. Food and Drug Administration Approves Bristol Myers Squibb’s COBENFY™ (xanomeline and trospium chloride), a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults	NYSE:BMY	Bristol Myers Squibb Co
2024/09/28	00 : 06	Business Wire	Bristol Myers Squibb Presents New Data from Two Trials Demonstrating Sotyktu (deucravacitinib) Efficacy in both Moderate-to-Severe Scalp Psoriasis and in a Real-World Setting	NYSE:BMY	Bristol Myers Squibb Co
2024/09/27	10 : 05	Business Wire	U.S. Food and Drug Administration Approves Bristol Myers Squibb’s COBENFY™ (xanomeline and trospium chloride), a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults	NYSE:BMY	Bristol Myers Squibb Co
2024/09/18	19 : 59	Business Wire	New Long-Term Zeposia (ozanimod) Data Demonstrate Durable Efficacy and Consistent Safety in Relapsing Forms of Multiple Sclerosis	NYSE:BMY	Bristol Myers Squibb Co
2024/09/15	21 : 55	Business Wire	Bristol Myers Squibb Presents Landmark 10-Year Follow-Up Data from CheckMate -067 Which Showed Continued Durable Long-Term Survival Benefit with Opdivo® plus Yervoy® in Advanced Melanoma	NYSE:BMY	Bristol Myers Squibb Co
2024/09/12	19 : 59	Business Wire	Bristol Myers Squibb to Report Results for Third Quarter 2024 on October 31, 2024	NYSE:BMY	Bristol Myers Squibb Co